Sanofi-Aventis appointed Euro RSCG Life to handle all communications programs for all new diabetes and thrombosis drugs while renewing the network’s global assignments on Lovenox/Clexane, Lantus and Apidra, which the Havas network has handled since 2004. The firm also named Euro RSCG C&O to handle corporate communications.